Related Experiment Video
Updated: May 15, 2026
A Murine Model of Group B Streptococcus Vaginal Colonization
Published on: November 16, 2016
Clinical management of the most common group A β-hemolytic streptococcal infections
1Department of Pediatrics, University of Minnesota Medical School, MMC 296 420 Delaware St. SE, Minneapolis, MN 55422, USA. kapla001@umn.edu
Abstract:
Group A streptococcal (Streptococcus pyogenes) infections remain important causes of medical and public health morbidity and mortality even during the early twenty-first century. Although most often concentrated in socially/economically disadvantaged populations, the problems remain significant in both industrializing and industrialized countries. The many M/emm types of GAS contribute to herd immunity in populations and also affect the control of streptococcal infections in these populations. Although this bacterium remains among the most susceptible to most antibiotics, it is evident that antibiotics alone have not solved the group A streptococcal medical and public health problems, even in those places where access to medical care is readily available. It is likely that the current streptococcal problems will remain difficult to manage and will remain essentially unchanged until the broad implementation of a cost-effective group A streptococcal vaccine, likely some years in the future.
Insights
Group A Streptococcus infections cause significant health problems globally. A cost-effective vaccine is needed for effective management, as antibiotics alone are insufficient.
Area of Science:
- Bacteriology
- Infectious Diseases
- Public Health
Background:
- Group A Streptococcus (Streptococcus pyogenes) infections are a persistent global health concern, causing significant morbidity and mortality.
- These infections disproportionately affect socially/economically disadvantaged populations but remain a problem in both industrializing and industrialized nations.
- The diverse M/emm types of GAS influence population herd immunity and complicate infection control strategies.
Purpose of the Study:
- To highlight the ongoing public health challenges posed by Group A Streptococcus infections.
- To emphasize the limitations of current antibiotic treatments in fully resolving GAS-related health issues.
- To underscore the critical need for a Group A Streptococcus vaccine.
Main Methods:
- This study is a review and synthesis of existing knowledge on Group A Streptococcus epidemiology and control.
- Analysis of the impact of M/emm types on population immunity and infection dynamics.
- Evaluation of the efficacy of antibiotic therapy versus the potential of vaccination.
Main Results:
- Group A Streptococcus infections continue to be a major cause of illness and death worldwide.
- Despite high susceptibility to antibiotics, current treatments have not eradicated the public health burden of GAS.
- The complexity of GAS strains and their impact on herd immunity present ongoing challenges.
Conclusions:
- Antibiotics alone are insufficient to solve the public health problems associated with Group A Streptococcus.
- A broadly implemented, cost-effective Group A Streptococcus vaccine is essential for future effective management.
- Vaccine development remains a critical, albeit distant, goal for controlling these infections.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
01:26Mitral Stenosis III: Medical Management
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:14Myocarditis III: Medical Management
01:30Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
01:18Endocarditis III: Medical Management